Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and CYP3A

NCT01576575
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine Control, Buprenorphine + Rifampin, Buprenorphine + Grapefruit juice, Buprenorphine + Ketoconazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
View directory record Official record
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase XI - 16

NCT00000234
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
25 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Results available

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

NCT05051644
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Steps 2 Change (S2C), Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 30, 2026, 4:25 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

NCT00000329
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 4:25 PM EDT
Completed No phase listed Observational

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery

NCT03604861
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-related Disorders
Interventions
Not applicable - no defined intervention
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
35
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Withdrawn Not applicable Interventional

Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment

NCT02033746
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Han's Acupoint Nerve Stimulator
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110
View directory record Official record
Conditions
Opioid Dependence, Injection Drug Use
Interventions
Community-based buprenorphine treatment (CBBT) intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Suboxone and PrEP Using Telemedicine

NCT04521920
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions
Suboxone, PrEP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

NCT03861338
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Sublocade
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 30, 2026, 4:25 PM EDT
Completed No phase listed Observational

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

NCT03583138
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Open-Label, Safety Study of Lofexidine

NCT02363998
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Lofexidine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Springdale, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 30, 2026, 4:25 PM EDT
Completed No phase listed Observational Results available

MOms in REcovery (MORE) Study: Defining Optimal Care

NCT04251208
View directory record Official record
Conditions
Opioid-Related Disorders, NAS, Substance Use Disorders, Mental Health
Interventions
Observational Study
Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Augusta, Maine • Bangor, Maine • Keene, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

NCT00000353
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
19 Years to 57 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 30, 2026, 4:25 PM EDT
Withdrawn Phase 2 Interventional

Olanzapine in OUD Patients

NCT05179772
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Olanzapine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Completed No phase listed Observational

Fetal Neurobehavior in Poly-drug Dependent Women

NCT00653692
View directory record Official record
Conditions
Poly Drug Exposed Pregnancies
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

Alternate-Day Buprenorphine Administration. Phase VII - 8

NCT00000226
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 48 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting No phase listed Observational

Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD

NCT05944133
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose, Death
Interventions
No intervention, observational retrospective study
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
16 Years and older
Enrollment
27,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

NCT03117140
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine, Ropivacaine 0.75% + 8 mg dexamethasone
Drug
Lead sponsor
Melinda Seering
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional

Directly Administered HIV Therapy in Methadone Clinics

NCT00279110
View directory record Official record
Conditions
HIV Infections, Heroin Dependence
Interventions
Directly administered antiretroviral therapy (DAART)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 30, 2026, 4:25 PM EDT